ImpriMed Builds a Live-Cell Evidence Engine for Oncology

ImpriMed built its human oncology business by starting with patients who could not wait for human medicine's timelines: dogs and cats with lymphoma. The Palo Alto company now operates across veterinary decision support, human blood-cancer research, and biopharma drug development, using living patient cells to measure how disease responds before an average result hides the individual case.

Co-founders Sungwon Lim, CEO, and Jamin Koo, CTO, started ImpriMed in 2017 after completing engineering doctorates at Stanford. Their platform combines ex vivo drug-response testing with genomic, immunophenotypic, clinical, and outcome data. The company matters now because functional precision medicine is moving from an interesting laboratory capability toward the harder work of standards, regulation, clinical evidence, and routine use.

ImpriMed reports more than 27,000 veterinary lymphoma tests across more than 600 hospitals in five countries. It is using that operating history to build human oncology products and a contract research business for blood-cancer drug developers. The veterinary scale is a valuable evidence engine, but it is not a shortcut around the proof required in human care.

Why Veterinary Oncology Became ImpriMed's Data Engine

ImpriMed was founded to work on human cancer, but veterinary oncology offered a faster path to commercial use and longitudinal outcomes. Treatment cycles move more quickly, veterinarians can follow response and survival over shorter periods, and the company can compare what its models predicted with what happened after clinicians made their own treatment decisions.

That loop created an asset most laboratory platforms do not get automatically: a growing record connecting live-cell measurements, model output, chosen therapy, and real outcomes. ImpriMed's veterinary platform now includes flow cytometry, clonality testing, and personalized prediction products for canine and feline blood cancers. The work also forced the company to learn sample logistics, laboratory consistency, clinician communication, and the limits of algorithmic confidence in real care.

The evidence is meaningful and bounded. A peer-reviewed retrospective study associated prediction-matched treatment with better response and survival in relapsed canine B-cell lymphoma. That supports the veterinary use case; it does not prove human clinical benefit, and the distinction matters more as ImpriMed crosses markets.

How xCellSense Turns Living Cells Into Evidence

ImpriMed's xCellSense platform keeps patient-derived blood-cancer cells viable outside the body and measures response to candidate drugs. For acute myeloid leukemia and acute lymphoblastic leukemia, the company describes testing across as many as 21 chemotherapeutic agents with results returned within seven days.

The live-cell measurement is only the first layer. ImpriMed combines dose-response data with flow cytometry, genomics, immunophenotyping, clinical history, and outcomes. Its machine-learning layer can then classify response patterns, search for predictive biomarkers, and separate potential responder groups from non-responders. The company says its broader model-development work draws on more than 3.5M data points.

For biopharma teams, ImpriMed has turned that system into Research Use Only CRO services. Sponsors can test individual compounds or combinations across primary patient samples, add sequencing and transcriptomic work, examine response in specific cell populations, and receive the raw and interpreted data. The useful product is not a mysterious score; it is a study system that keeps fragile cells alive long enough to produce reproducible evidence.

Where the Business Sits Today

ImpriMed now serves three related customers. Veterinary oncologists use its commercial tests to add functional and predictive information to treatment decisions. Human oncology researchers are evaluating products for blood cancers including AML, ALL, non-Hodgkin lymphoma, and multiple myeloma. Biotech and pharmaceutical teams can use xCellSense to study candidates, combinations, resistance, biomarkers, and patient stratification before or alongside clinical development.

The company operates laboratories in Silicon Valley and Seoul. ImpriMed says the U.S. laboratory holds ISO 17025 accreditation through A2LA, while the Seoul laboratory operates under KGMP and holds an IVD Medical Device Manufacturing License. Its U.S. human predictions remain for research and investigational use, and its CRO services remain Research Use Only.

That qualification is not legal footnote clutter. It defines the commercial crossing in front of ImpriMed. A veterinary product, a research assay, a sponsor-facing service, and a regulated clinical decision tool can share technology, but they carry different evidence, quality, reimbursement, and workflow requirements.

Leadership and the Operating Model

Lim and Koo built ImpriMed around a combined biology, engineering, and data problem. The current leadership team also includes Chief Commercial Officer Valerie Goodwin-Adams, Vice President of Sales Operations Mary Frye, Director of Regulatory Affairs and Quality Assurance James Park, and Chief of Staff Sung Yeon Hwang, according to the company's official team page.

The organization has to make several disciplines work as one operating system. Laboratory teams must preserve sample viability and generate repeatable readouts. Data scientists must build models that remain interpretable under clinical scrutiny. Commercial and customer teams must translate results for veterinarians, physicians, and drug developers without presenting research evidence as certainty.

That cross-functional burden explains why ImpriMed's path began with a real market instead of a pristine research sandbox. More than 27,000 veterinary tests represent not only data volume but repeated handoffs among hospitals, couriers, laboratories, software, clinicians, and patient outcomes. Human oncology raises the standard for every one of those handoffs.

Why ImpriMed's Hiring Is a Market Signal

ImpriMed's careers page describes a team built around curiosity, problem solving, communication, cross-functional work, and commitment to cancer care. It currently lists an onsite laboratory role in Palo Alto, while recent company recruiting has also emphasized assay validation, flow cytometry, and CLIA accreditation.

Those roles reveal where the company is spending organizational attention. ImpriMed is not hiring only to produce more software features or sales coverage. Laboratory quality, regulatory operations, clinical validation, and sample workflows are the infrastructure required to convert a research platform into a service that hospitals and regulators can trust.

The company's September 2026 $10M Series A2 bridge gives that transition fresh capital. ImpriMed is targeting FDA clearance and CLIA certification for initial human products by Q1 2027, expanding its U.S. hospital relationships, and growing its CRO work. Those are company targets rather than completed milestones, which makes execution talent more important than the funding headline.

What ImpriMed Must Prove Next

The National Cancer Institute is giving functional precision medicine more institutional attention because living cells can reveal treatment response that genomic signals may miss. NCI also identifies the unfinished work: viable-tissue logistics, assay standards, rigorous clinical evidence, regulatory acceptance, reimbursement, and integration into oncology practice.

ImpriMed arrives at that moment with an unusual advantage. It has commercial laboratory experience, an outcome-linked veterinary dataset, human research collaborations, and a CRO product built around primary blood-cancer samples. The company also carries an equally unusual obligation to show that these assets transfer without overstating what veterinary and retrospective evidence can establish.

The next proof will not be another model metric in isolation. It will be whether ImpriMed can make live-cell response reproducible across sites, useful inside treatment workflows, credible to regulators, and predictive in prospective human evidence. Veterinary oncology taught the company how to run the loop; human oncology will decide whether the loop is strong enough to change care.